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The acu-meny: A new device for continuous renal replacement
therapy in acute renal failure
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The acu-meny: A new device for continuous renal replacement therapy in
acute renal failure.
Background. We sought to design a simple machine to safely provide
continuous veno-venous hemofiltration to acute renal failure patients.
Results. The acu-meny device uses a pneumatic blood pump with tidal
blood flow as the driving force. A volumetric balancing system balances
the filtrate with the replacement fluid, and the blood—air interface is
eliminated by replacing the conventional venous drip chamber with two
air-separating membranes. The extracorporeal circuit is integrated in a
disposable cartridge, which is inserted into the machine at the beginning
of treatment. The priming and rinsing is done automatically.
Conclusion. While preliminary data from an ongoing clinical trial on the
efficacy of this device are encouraging, further longer-term studies are
necessary to evaluate its potential to decrease morbidity and mortality in
acute renal failure patients.
Continuous renal replacement therapy (CRRT) was
pioneered as continuous arterio-venous hemofiltration
(CAVH) by Kramer et al 20 years ago [1]. The goal was to
provide renal replacement therapy without a complicated
device, however, the limitations of this simple therapy have
triggered the development of many elaborate devices [2].
What started with CAVH as a simple treatment modality
has evolved into a complex therapy, utilizing sophisticated
machines with various pumps and numerous safety fea-
tures. With the increasing complexity of the machines, the
ongoing monitoring of pressures, fluid balance, anticoagu-
lation parameters and filter efficacy involves a tremendous
work load in most instances. We have developed a new
machine to further enhance the safety and efficiency of
CRRT, but at the same time make the extracorporeal
circuit less complex and easier to operate.
The purpose of this article is to describe a new system for
continuous veno-venous hemofiltration and to outline its
clinical implications. The acu-meny utilizes a pneumatic
blood pump with a tidal blood flow as the driving force (Fig.
1). A volumetric balancing system is used to balance filtrate
with replacement fluid. The blood–air interface is elimi-
nated by replacing the venous drip chamber with air-
separating membranes. Furthermore, the device comprises
a disposable cartridge for the extracorporeal circuit, auto-
matic priming, “one-button” operation, battery back-up
and the possibility to operate with a single or double lumen
access.
Cartridge system and pneumatic blood pump
The extracorporeal circuit is integrated in a disposable,
ETO-sterilized cartridge, which contains a pneumatic
blood pump, a pneumatic heparin pump, a volumetric
balancing chamber, two air separating membranes, a he-
mofilter (AV-400 or AV-600) and all the blood tubing (Fig.
2). Both hemofilters consist of polysulfone with a surface
area of 0.75 m2 and 1.4 m2, a capillary lumen of 220 mm and
a wall thickness of 35 mm. Set-up is easily accomplished
within minutes by simple insertion of the cartridge into the
machine and closing the door (Fig. 1). Priming and rinsing
is done automatically.
A pneumatic blood pump (membrane pump) is utilized
to drive the blood through the extracorporeal circuit (Fig.
3). The pump works in two cycles. At the first cycle, a
negative pressure is generated that fills the pump with
blood (Fig. 4A). The positive pressure of the next cycle
drives the blood through the filter and back to the patient
(Fig. 4B). The stroke volume of the blood pump is 25 ml
and determines the stroke frequency for a given blood flow;
for example, in order to deliver a blood flow of 100 ml/min,
the pump will fill and empty 4 times/min. The pump works
with negative arterial pressures of roughly 200 to 300 mm
Hg and positive venous pressures of approximately 150 to
250 mm Hg.
The pneumatic heparin pump works also in two cycles.
At the negative pressure cycle, heparinized saline is drawn
from a syringe and fills the heparin pump. The positive
pressure of the subsequent cycle pushes the heparin into
the arterial line of the extracorporeal circuit.
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Volumetric balancing and fluid removal
As blood passes through the filter, filtrate is produced
and runs into the volumetric balancing chamber. The
volumetric balancing chamber has a volume of 5 ml and
consists of two chambers that are separated by a non-
permeable silicone membrane. One chamber contains the
filtrate, and the other chamber the replacement fluid. In
the negative pressure cycle (when the blood pump is being
filled with blood), 5 ml replacement fluid runs into the
balancing chamber, presses the membrane towards the
opposite (left) wall of the chamber, and pushes the filtrate
into the waste bag. Five milliliters of filtrate are produced
in the next positive pressure cycle (when blood runs
through the filter and back to the patient) and fill the
balancing chamber completely (Fig. 4B). The membrane is
pressed against the opposite (right) wall and 5 ml replace-
ment fluid are pushed to the venous line of the extracor-
poreal circuit. Hence, a one-to-one relationship between
filtrate and replacement fluid is ensured. Driving forces for
the membrane within the balancing chamber are the posi-
tive pressure from the height of the replacement fluid bag,
the negative pressure from the depth of the waste bag, the
filtration pressure, and the tension of the membrane. No
pump is necessary to control the flow of replacement fluid
and filtrate. The balancing system works with an error of
,1%, which has been validated in vitro for 96 hours.
Net fluid removal is accomplished by automatic, tempo-
rary closure of the replacement fluid outflow line from the
balancing chamber to the extracorporeal circuit (Fig. 4C).
If this line is closed and the replacement fluid inflow line
remains open, the produced filtrate pushes the replacement
fluid from the balancing chamber back to the replacement
fluid bag and not to the venous line. At this point, the
filtrate is not replaced and net fluid removal is accom-
plished.
Complete filling of the balancing chamber is detected by
the chamber filling sensor in the replacement fluid line
(Fig. 4A). In the negative pressure cycle, replacement fluid
flows from the replacement fluid bag into the balancing
chamber. Driving force is the pressure caused by gravity
and the height of the replacement fluid bag. The pressure
peaks abruptly once the balancing chamber is completely
filled and the membrane touches the left wall. The pressure
sensor measures this peak pressure and the time when it
occurs.
Relationship between blood flow and filtrate volume
The volume of filtrate and replacement fluid is automat-
ically controlled by the blood pump. Exactly 20% of the
blood that passes the filter is filtered. This 5:1 relationship
between blood flow and filtrate volume is determined by
the size of the blood pump (25 ml) and the size of the
balancing chamber (5 ml). With each 25 ml stroke of the
blood pump, exactly 5 ml or 20% are filtered. By limiting
the ratio between filtrate volume and blood flow to 20%,
the device avoids hemoconcentration towards the end of
the filter. Once the desired filtrate volume is set, the blood
flow is automatically adjusted to achieve the optimal fil-
trate/blood flow ratio of 20%. A blood flow of 140 ml/min
will deliver 1.68 liters of filtrate per hour [(140 ml/min: 5) 3
60 min], a blood flow of 120 ml/min 5 1.44 liters, and a
desired filtrate volume of 1.2 liter/hr requires a blood flow
of 100 ml/min.
Air-separating membranes
Two hydrophobic, polytetrafluorethylene air-separating
membranes (Gore, Putzbrunn, Germany) replace the func-
tion of the arterial and venous drip chamber and com-
pletely avoid any blood—air interface within the circuit
(Fig. 3). The arterial/pre-filter membrane is located at the
highest point of the blood pump, the venous/post-filter
membrane is at the highest point of the venous line.
Negative pressure is applied at the back side of these
membranes. As blood passes along the membranes, the
negative pressure continuously sucks out any air bubbles
that might have entered the extracorporeal circuit. By
avoiding the obligatory blood–air contact within the drip
chamber of conventional devices, the circuit is more bio-
compatible with less activation of the clotting system. The
accuracy of the air removal is monitored by an ultrasonic
Fig. 1. The acu-meny device with the cartridge inserted and door open.
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air bubble detector at the venous side, which shuts off the
blood pump if the membranes fail to extract all the air.
Operational features of the blood pump
Single lumen access. All available devices for continuous
renal replacement therapy use a roller pump to create a
constant blood flow through the extracorporeal circuit [2].
Utilization of a pneumatic blood pump by the acu-meny
results in a tidal blood flow, which makes it possible to
operate the device with a single or double lumen access. At
the same external diameter, single lumen catheters have a
larger internal diameter than double or triple lumen cath-
eters and can more easily provide higher blood flows [3].
Furthermore, the alternating flow direction (pull and push)
within the single lumen access might contribute to fewer
incidents of access clotting.
Fig. 2. The acu-meny cartridge.
Fig. 3. Pneumatic blood pump.
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Fig. 4. Operation of the acu-meny machine in
the continuous veno-venous hemofiltration
mode. (A) Negative pressure cycle. The blood
pump creates a negative pressure and blood
runs from the patient to the blood pump. In
the balancing chamber, valves 3 and 4 are
closed and valves 5 and 6 are open, enabling
replacement fluid to flow from the replacement
fluid bag into the balancing chamber and
filtrate to flow from the balancing chamber into
the waste bag. The driving force is gravity, with
the positive pressure from the height of the
replacement fluid bag and the negative
pressure from the depth of the waste bag. (B)
Positive pressure cycle with 1:1 exchange. The
blood pump creates a positive pressure that
drives the blood through the filter and back to
the patient. In the balancing chamber, valves 5
and 6 are closed and valves 3 and 4 are open.
This enables production of filtrate through the
filter into the balancing chamber, and flow of
replacement fluid from the balancing chamber
into the venous line of the extracorporeal
circuit. The driving force is the filtrate pressure
and the tension of the membrane. (C) Positive
pressure cycle with fluid removal. The blood
pump creates a positive pressure that drives
the blood through the filter and back to the
patient. In the balancing chamber, valves 5 and
4 are closed and valves 3 and 6 are open,
enabling the production of filtrate through the
filter into the balancing chamber. Since valve 4
is closed and valve 6 is open, the replacement
fluid is pushed from the balancing chamber to
the replacement fluid bag, and the filtrate is
not replaced in this cycle.
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Tidal blood flow. The permeability of the filter decreases
over time in devices with a roller pump and continuous
blood flow [4]. Sigler and Teehan observed a 50% fall in
ultrafiltration rate in the first 20 hours of continuous
arterio-venous hemodialysis [5]. The decrease showed a
logarithmic pattern with a rapid fall during the first six
hours and a minimal decline over the next 18 hours. The
time-dependent decrease of membrane function was pos-
sibly due to membrane protein absorption, concentration
polarization and partial clotting [6]. Jenkins et al showed
that the fall in hydraulic permeability over time also occurs
if the membrane is exposed to water or saline, suggesting
that at least one more unidentified factor contributes to the
permeability decay [7].
Utilization of a pneumatic blood pump by the acu-meny
results in a tidal blood flow. It has been shown that tidal
blood flow enhances the plasma filtration rate of hollow
fiber filters during plasmapheresis [8]. Furthermore, the
time-dependent fall in plasma filtration rate during plas-
mapheresis was less with tidal blood flow than with contin-
uous blood flow [9]. The described system produced a
retrograde wave that temporarily reversed the blood flow
direction within the filter. Furthermore, it allowed for some
degree of backfiltration during the down time of the blood
pump. This and the rapid acceleration of the blood with
velocity spikes presumably dislodged molecules from the
membrane and cleaned the filter surface [10]. Hence, tidal
blood flow has the potential to reduce protein absorption
and concentration polarization, and thus to delay the
decline in filter permeability.
Activation of the coagulation system
A potential drawback of continuous renal replacement
therapy (CRRT) is the ongoing necessity for continuous
anticoagulation to prevent clotting of the extracorporeal
circuit. The interaction between the blood and the dialyzer
surface, the blood–air contact within the venous drip
chamber and the particle filter within the venous drip
chamber promote the activation of the clotting system with
subsequent thrombus formation [11–13].
Keller et al studied the risk factors of systemic clotting
during 296 heparin-free hemodialysis sessions in 84 pa-
tients [14]. They found that the venous drip chamber and
the dialyzer or hemofilter are the two sides where clotting
usually starts. Thrombus formation occurred more fre-
quently in the venous drip chamber than in the dialyzer
(78% vs. 22%). Furthermore, it was observed that clotting
in the drip chamber frequently precedes filter clotting [2].
Two mechanisms have been identified for clotting activa-
tion within the drip chamber: (1) flow separation with areas
of stagnant blood, where a fraction of the blood flow is
excluded from the continuous flow and has prolonged
contact with air and the artificial surface of the drip
chamber [15, 16]; and (2) blood–air contact, which amounts
to roughly 5 to 6 cm2 in conventional drip chambers [17].
Some devices use an arterial (pre-filter) drip chamber to
catch air bubbles before they reach the filter, which adds
approximately 2 to 4 cm2 to the blood–air interface.
Several modifications have been employed to reduce the
blood–air contact within the drip chamber. Kitamoto et al
describe an extracorporeal system in which a triglyceride
(NOF-005) is floated over the blood in the chamber [18,
19], and the triglyceride layer shields the blood from the air.
Clotting and thrombin-antithrombin III generation were
decreased compared to a control group, who were treated
with conventional extracorporeal circuits. Gretz et al mod-
ified the venous blood chamber by extending the inlet blood
line so that the blood level in the venous chamber rises
about 1 cm above the inlet level of the venous blood line
[20]. This allows for blood sedimentation during the dialysis
session, which leaves a plasma layer on top of the circulat-
ing blood. The layer acts as an air lock and seems to reduce
clotting.
The acu-meny has replaced the function of the arterial
and venous drip chamber by two air-separating mem-
branes. Thus, the blood–air contact within the extracorpo-
real circuit is completely eliminated, which might translate
into less clotting activation and possibly an extended filter
lifespan.
Several authors recommend to limit the filtration frac-
tion (filtration rate/plasma flow rate) to 20 to 30%, as
higher filtration fractions promote clotting [21, 22]. As
water is removed by ultrafiltration, plasma proteins, oncotic
pressure and hematocrit are rising. The greater viscosity
towards the end of the filter increases the resistance of the
filter and promotes clotting. The acu-meny employs a fixed
5:1 relationship between blood flow and filtrate volume.
Once the desired filtrate volume is set, the device will
automatically adjust the blood flow to achieve an optimal
filtrate/blood flow ratio of 20%.
Balancing
Accurate fluid balance (dialysate inflow with dialysate
outflow; filtrate with replacement fluid) and precise volume
removal is a major problem in continuous treatments [23].
Volume removal is either achieved by means of gravity,
where the depth of the drainage bag location determines
the negative pressure in the filtrate compartment, or by
utilizing an ultrafiltration pump, which creates a negative
pressure in the filtrate compartment [24].
Balance of filtrate with replacement fluid can be accom-
plished with calibrated filtrate collecting vessels, where the
replacement fluid infusion rate is adjusted hourly to the
filtrate volume of the previous hour. This procedure is very
time consuming and often impracticable.
For continuous veno-venous hemodialysis (CVVHD), it
has been suggested to insert both tubings for dialysate
inflow and outflow into one pump head [25]. In this system,
fluid removal is facilitated by an Y-connection inserted into
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the dialysate outlet and connected to an infusion pump.
This method has not found widespread acceptance.
Another technique to achieve fluid balance is the use of
two identically calibrated pumps (one for the replacement
fluid and one for the filtrate) [26]. The operation of two
independent working pumps should be avoided. If the
infusion pump for the replacement fluid stops, and the
pump for the filtrate continues, large fluid losses can occur
in a short time. While electrically linked pumps provide
more safety in this setting [24], calibrating differences
between both pumps can still generate large errors in fluid
delivery and removal, and thus may result in hazardous
total balancing errors and severe extracellular fluid deple-
tion of up to 2.4 liter/day [23, 25, 27, 28].
Gravimetric balancing, which uses two scales for the
replacement fluid and the filtrate, provide more accurate
fluid balance. However, the scales are alarm sensitive
against external motion, which can occasionally lead to
frequent alarms and blood pump stops that in turn increase
the workload and promote clotting.
Volumetric balancing provides an accurate fluid balance
of . 99%, which significantly increases the reliability and
safety of continuous renal replacement therapy. Volumet-
ric balancing is motion resistant, and since the balancing
system is integrated into the machine/cartridge it will
automatically pause if the blood pump stops or alarm if one
side of the balancing circuit is disordered (such as with
empty replacement fluid bag or full filtrate bag).
All conventional devices for continuous renal replace-
ment therapy have at least four features in common (Table
1): (1) They use a roller pump to drive the blood through
the extracorporeal circuit. (2) The roller pump provides a
continuous blood flow. (3) Balancing of filtrate with re-
placement fluid is either attained manually, or with two
pumps or two scales. (4) A venous drip chamber is used to
catch air bubbles [with the exception of the Prismay
(Hospal, Lyon, France), which does not have a venous drip
chamber]. The acu-meny utilizes a pneumatic blood pump
with a tidal blood flow as the driving force. Furthermore, a
volumetric balancing system is used to balance filtrate with
replacement fluid. The blood–air interface is eliminated by
replacing the venous drip chamber with air-separating
membranes. Preliminary data from an ongoing clinical trial
confirm the performance of the device; however, the pos-
sible clinical advantages for morbidity and mortality needs
to be evaluated in future studies.
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